141 related articles for article (PubMed ID: 20696683)
1. Tissue microarray construction from gross specimens: development of a novel simple technique.
Sharma SK; Deka L; Gupta R; Gupta S; Singh DK; Singh S
J Clin Pathol; 2010 Sep; 63(9):782-5. PubMed ID: 20696683
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
[TBL] [Abstract][Full Text] [Related]
3. Loss of antigenicity in stored sections of breast cancer tissue microarrays.
Fergenbaum JH; Garcia-Closas M; Hewitt SM; Lissowska J; Sakoda LC; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):667-72. PubMed ID: 15066936
[TBL] [Abstract][Full Text] [Related]
4. Application of a novel and low cost technique to construct paraffin tissue microarrays out of paraffinised needle biopsy specimens from patients with breast cancer.
Vogel UF; Bültmann B
J Clin Pathol; 2010 Jul; 63(7):640-3. PubMed ID: 20591915
[TBL] [Abstract][Full Text] [Related]
5. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
J Clin Pathol; 2007 Apr; 60(4):397-404. PubMed ID: 16775123
[TBL] [Abstract][Full Text] [Related]
6. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
8. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
[TBL] [Abstract][Full Text] [Related]
9. Validation of tissue microarray technology in endometrioid cancer of the endometrium.
Fons G; Hasibuan SM; van der Velden J; ten Kate FJ
J Clin Pathol; 2007 May; 60(5):500-3. PubMed ID: 16822874
[TBL] [Abstract][Full Text] [Related]
10. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarray (TMA) versus whole section immunohistochemistry in the assessment of ER/PR and Her-2/neu status in a breast cancer series from Sudan.
Awadelkarim KD; Arizzi C; Elamin EO; Osman I; Mekki SO; Biunno I; Barberis MC; Mariani-Costantini R
Breast J; 2013; 19(4):446-7. PubMed ID: 23721068
[No Abstract] [Full Text] [Related]
12. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination.
Pegolo E; Machin P; Riosa F; Bassini A; Deroma L; Di Loreto C
Cancer Cytopathol; 2012 Jun; 120(3):196-205. PubMed ID: 22298467
[TBL] [Abstract][Full Text] [Related]
13. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
[TBL] [Abstract][Full Text] [Related]
14. Application of new tissue microarrayer-ZM-1 without recipient paraffin block.
Meng PQ; Hou G; Zhou GY; Peng JP; Dong Q; Zheng S
J Zhejiang Univ Sci B; 2005 Sep; 6(9):853-8. PubMed ID: 16130184
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarrays: construction and uses.
Fowler CB; Man YG; Zhang S; O'Leary TJ; Mason JT; Cunningham RE
Methods Mol Biol; 2011; 724():23-35. PubMed ID: 21370004
[TBL] [Abstract][Full Text] [Related]
16. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.
Amir E; Ooi WS; Simmons C; Kahn H; Christakis M; Popovic S; Kalina M; Chesney A; Singh G; Clemons M
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):763-8. PubMed ID: 18824337
[TBL] [Abstract][Full Text] [Related]
17. Validation of tissue microarray biomarker expression of breast carcinomas in Saudi women.
Alkushi A
Hematol Oncol Stem Cell Ther; 2009; 2(3):394-8. PubMed ID: 20139052
[TBL] [Abstract][Full Text] [Related]
18. Implementation of TMA and digitalization in routine diagnostics of breast pathology.
Rossing HH; Talman ML; Laenkholm AV; Wielenga VT
APMIS; 2012 Apr; 120(4):341-7. PubMed ID: 22429216
[TBL] [Abstract][Full Text] [Related]
19. Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory.
Thomson TA; Zhou C; Chu C; Knight B
Am J Clin Pathol; 2009 Dec; 132(6):899-905. PubMed ID: 19926582
[TBL] [Abstract][Full Text] [Related]
20. Hypodermic needle without recipient paraffin block technique.
Pires AR; de Souza SR
Methods Mol Biol; 2010; 664():53-61. PubMed ID: 20690052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
